Benign multiple sclerosis, old age, and cognitive impairment: Is teriflunomide an appropriate treatment for this clinical triad?

Benign multiple sclerosis, old age, and cognitive impairment: Is teriflunomide an appropriate treatment for this clinical triad?

Bibliographic Details
Main Author:	D.A. García Estévez
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	Neurology Perspectives
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667049621000399

Similar Items

Teriflunomide in patients with multiple sclerosis
by: N. Y. Lasch, et al.
Published: (2015-12-01)

An update of teriflunomide for treatment of multiple sclerosis
by: Oh J, et al.
Published: (2013-04-01)

Role of oral teriflunomide in the management of multiple sclerosis
by: Tanasescu R, et al.
Published: (2013-04-01)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
by: Carlo Tornatore, et al.
Published: (2022-02-01)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
by: Clemens Warnke, et al.
Published: (2009-05-01)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
by: Boris A. Kallmann, et al.
Published: (2021-05-01)

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
by: Jiwon Oh, et al.
Published: (2014-09-01)

Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain
by: Lamberto Landete, et al.
Published: (2021-10-01)

Analysis of medication persistence and reasons for discontinuation of treatment with teriflunomide and dimethyl fumarate in a hospital series of patients with multiple sclerosis
by: D.A. García Estévez, et al.
Published: (2022-07-01)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
by: Giancarlo Comi, et al.
Published: (2020-10-01)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
by: Steffen Pfeuffer, et al.
Published: (2021-03-01)

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
by: Gaëlle Tilly, et al.
Published: (2021-10-01)

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
by: Aaron E. Miller
Published: (2017-12-01)

Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis
by: N. Y. Lasch
Published: (2015-12-01)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
by: Bayas A, et al.
Published: (2015-02-01)

Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
by: María Inmaculada Domínguez-Mozo, et al.
Published: (2023-09-01)

Remission of hereditary angioedema attacks associated with starting teriflunomide in a patient with multiple sclerosis
by: Ana López, et al.
Published: (2023-03-01)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
by: Greene N, et al.
Published: (2022-12-01)

Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies
by: Jiwon Oh, et al.
Published: (2021-07-01)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
by: Steve Vucic, et al.
Published: (2022-08-01)

Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study
by: M.L. Martínez-Ginés, et al.
Published: (2023-10-01)

Real-world data on the effectiveness and safety of teriflunomide in patients with relapsing–remitting multiple sclerosis: The EFFECT study
by: Mª.C. Durán Herrera, et al.
Published: (2022-07-01)

Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis
by: Lisa Thiele née Schrewe, et al.
Published: (2020-01-01)

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
by: Boris A. Kallmann, et al.
Published: (2019-03-01)

Cognitive Impairment in Multiple Sclerosis
by: Kenneth Maiese
Published: (2023-07-01)

Cognitive Impairment in Multiple Sclerosis
by: Trenova Anastasiya G., et al.
Published: (2016-09-01)

Cognitive impairment in multiple sclerosis
by: Kutashov V.A., et al.
Published: (2016-06-01)

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
by: Viktoria Papp, et al.
Published: (2021-01-01)

Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role
by: Hongmei Tan, et al.
Published: (2024-03-01)

Acute Ischemic Stroke in a Patient with Multiple Sclerosis after Initiating Teriflunomide Treatment: A Challenging Case
by: Arsh Haj Mohamad Ebrahim Ketabforoush, MD, et al.
Published: (2024-01-01)

TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)
by: E. V. POPOVA, et al.
Published: (2016-12-01)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
by: José E. Meca-Lallana, et al.
Published: (2023-10-01)

The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis
by: Bitao Bu, et al.
Published: (2023-07-01)

Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study
by: Wei Qiu, et al.
Published: (2018-01-01)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
by: Emanuele D’Amico, et al.
Published: (2018-09-01)

Lichenoid drug eruption induced by teriflunomide
by: Fatima-Zahra Agharbi, et al.
Published: (2023-01-01)

Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes
by: Bruno Brochet, et al.
Published: (2019-03-01)

Network collapse and cognitive impairment in multiple sclerosis
by: Menno Michiel Schoonheim, et al.
Published: (2015-04-01)

Cognitive impairment in relapsing remitting Multiple Sclerosis
by: Saška Roškar
Published: (2003-06-01)

Early and severe cognitive impairment in multiple sclerosis
by: Maria Fernanda Mendes, et al.